HighPoint Advisor Group LLC lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 11.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 63,680 shares of the company’s stock after acquiring an additional 6,357 shares during the quarter. Johnson & Johnson accounts for about 2.3% of HighPoint Advisor Group LLC’s holdings, making the stock its 7th largest position. HighPoint Advisor Group LLC’s holdings in Johnson & Johnson were worth $8,647,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Evolution Wealth Advisors LLC purchased a new stake in Johnson & Johnson in the fourth quarter worth $40,000. Crewe Advisors LLC increased its position in Johnson & Johnson by 75.0% in the fourth quarter. Crewe Advisors LLC now owns 350 shares of the company’s stock worth $45,000 after buying an additional 150 shares during the last quarter. Horan Securities Inc. increased its position in Johnson & Johnson by 122.3% in the fourth quarter. Horan Securities Inc. now owns 438 shares of the company’s stock worth $56,000 after buying an additional 241 shares during the last quarter. Stuart Chaussee & Associates Inc. increased its position in Johnson & Johnson by 20.7% in the fourth quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock worth $60,000 after buying an additional 80 shares during the last quarter. Finally, Ruggie Capital Group increased its position in Johnson & Johnson by 342.5% in the fourth quarter. Ruggie Capital Group now owns 469 shares of the company’s stock worth $60,000 after buying an additional 363 shares during the last quarter. 66.90% of the stock is owned by institutional investors.

A number of research firms have issued reports on JNJ. Credit Suisse Group raised their target price on Johnson & Johnson from $151.00 to $152.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 17th. Raymond James raised their target price on Johnson & Johnson from $145.00 to $147.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 17th. Wells Fargo & Co reissued an “outperform” rating and issued a $157.00 target price (up from $152.00) on shares of Johnson & Johnson in a research report on Monday, May 6th. BMO Capital Markets raised their price target on Johnson & Johnson from $154.00 to $157.00 and gave the stock an “outperform” rating in a report on Wednesday, April 17th. Finally, Goldman Sachs Group initiated coverage on Johnson & Johnson in a report on Tuesday, May 28th. They issued a “buy” rating for the company. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Johnson & Johnson currently has a consensus rating of “Buy” and a consensus price target of $147.30.

In related news, Director Marillyn A. Hewson purchased 3,000 shares of the business’s stock in a transaction dated Tuesday, June 11th. The stock was purchased at an average cost of $139.68 per share, with a total value of $419,040.00. Following the completion of the acquisition, the director now directly owns 3,000 shares of the company’s stock, valued at $419,040. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.23% of the stock is owned by company insiders.

Johnson & Johnson stock opened at $140.09 on Friday. Johnson & Johnson has a one year low of $120.11 and a one year high of $148.99. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.44 and a quick ratio of 1.13. The firm has a market capitalization of $371.95 billion, a PE ratio of 17.13, a P/E/G ratio of 2.43 and a beta of 0.70.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 16th. The company reported $2.10 EPS for the quarter, topping the Zacks’ consensus estimate of $2.03 by $0.07. Johnson & Johnson had a return on equity of 36.29% and a net margin of 17.99%. The firm had revenue of $20.02 billion during the quarter, compared to analyst estimates of $19.55 billion. During the same period last year, the company earned $2.06 earnings per share. The business’s revenue for the quarter was up .1% on a year-over-year basis. Analysts anticipate that Johnson & Johnson will post 8.6 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 11th. Stockholders of record on Tuesday, May 28th were issued a $0.95 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.90. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.71%. The ex-dividend date was Friday, May 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.45%.

COPYRIGHT VIOLATION NOTICE: “HighPoint Advisor Group LLC Raises Position in Johnson & Johnson (NYSE:JNJ)” was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://theolympiareport.com/2019/06/16/highpoint-advisor-group-llc-raises-position-in-johnson-johnson-nysejnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Systematic Risk

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.